PATENT CLAIM ANALYSIS

Application Number: 16038924
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "249000"]

Abstract:
The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Claim (Index 50):
The method of  claim 1 , wherein the compound is a compound having Formula Va: or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 95.0
- Lexical Diversity: 1.16216
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15610015', '14795536', '14795532', '15670094', '14795466']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8376146005731171
- 35 USC 102 Novelty (BERT): 0.6826690026637284
- Combined Prediction Score: 0.8221200407821783
- Mean Citation Score: 611.988482
- Max Citation Score: 707.0113
- Similarity Product: 650.7027911911249

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test